drugset

Drugs / JNJ-79635322

Follow last change Jul 2026 re-read 2 minutes ago

JNJ-79635322

also known as Ramantamig

targets GPRC5D via depletion

Developed for: plasma cell myeloma · AL amyloidosis · refractory plasma cell neoplasm
Investigated by: Janssen Research & Development, LLC · Deutsche Studiengruppe Multiples Myelom (DSMM) · University of Heidelberg Medical Center

Trials 8 · a red edge is where a trial was stopped

today NCT07665450 · Ph 3 NCT07518186 · Ph 3 NCT07266441 · Ph 2 NCT07258511 · Ph 3 NCT06768489 · Ph 1 NCT06500884 · Ph 2 NCT05695508 · Ph 2 NCT05652335 · Ph 1

20232024202520262027202820292030

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT06768489	Dec 2024 → Jan 2029 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 1	NCT05652335	Nov 2022 → Apr 2027 expected	AL amyloidosis, refractory plasma cell neoplasm	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 23 trials
Phase 2	NCT07266441	Feb 2026 → Jun 2027 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT06500884	Aug 2024 → May 2030 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT05695508	Dec 2022 → Sep 2028 expected	plasma cell myeloma	University of Heidelberg Medical Center	Recruiting	No outcome recorded
Phase 33 trials
Phase 3	NCT07665450	Sep 2026 → Sep 2030 expected	plasma cell myeloma	Janssen Research & Development, LLC	Not yet recruiting	No outcome recorded
Phase 3	NCT07518186	May 2026 → Apr 2029 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded
Phase 3	NCT07258511	Feb 2026 → Dec 2028 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT07589634 Background	Jul 2026 → Dec 2027 expected	plasma cell myeloma	Janssen Research & Development, LLC	Recruiting	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	JNJ-79635322	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07258511 ↗ 5 NCT07518186 ↗ NCT07266441 ↗ NCT05695508 ↗ NCT05652335 ↗ NCT06768489 ↗
Known as	Ramantamig	“Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody” PMID 41100731 ↗ Feb 2026 3 NCT07665450 ↗ NCT07589634 ↗ NCT06500884 ↗
Action	Deplete	“resulting in efficient depletion of the malignant clonal populations” PMID 41100731 ↗ Feb 2026
Route	Subcutaneous	“JNJ-79635322 will be administered as SC injection.” NCT05652335 ↗
Target	GPRC5D	“targeting BCMA, GPRC5D, and CD3” PMID 41100731 ↗ Feb 2026